Fierce Pharma August 28, 2024
As Stada Arzneimittel’s private equity owners continue to weigh their options around a potential sale or public offering, the German drugmaker gave a good indication Wednesday of exactly what it can bring to the table.
Over the first six months of the year, Stada generated sales of 2.02 billion euros ($2.2 billion), growing revenues 9% compared with the same period in 2023, the company said in a release. For the same period that ended June 30, Stada grew earnings before interest, taxes, depreciation, and amortization by 11% to 465.3 million euros ($515 million).
All three of Stada’s business segments—consumer healthcare, generics and specialty pharma—contributed to the revenue growth, with specialty pharma delivering the biggest year-over-year change. The company also said...
Today's Sponsors
Today's Sponsor